LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.

03/27

LENZ Therapeutics, Inc. (NASDAQ:LENZ) just released its latest yearly report and things are not looking great. It was a pretty negative result overall, with revenues of US$19m missing analyst ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2622823417"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622823417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622823417?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-27 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622823417","market":"sg","top_or_hot":-1,"title":"LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know","media":"Simply Wall St.","content":"<div>\n<p>LENZ Therapeutics, Inc. (NASDAQ:LENZ) just released its latest yearly report and things are not looking great.      It was a pretty negative result overall, with revenues of US$19m missing analyst ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/news/lenz-therapeutics-inc-nasdaqlenz-analysts-are-cutting-their\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-03-27 18:24</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>LENZ Therapeutics, Inc. (NASDAQ:LENZ) just released its latest yearly report and things are not looking great.      It was a pretty negative result overall, with revenues of US$19m missing analyst ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/news/lenz-therapeutics-inc-nasdaqlenz-analysts-are-cutting-their\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/news/lenz-therapeutics-inc-nasdaqlenz-analysts-are-cutting-their\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QLD","symbol_name":"2倍做多納斯達克100指數ETF-ProShares","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/news/lenz-therapeutics-inc-nasdaqlenz-analysts-are-cutting-their","article_id":"2622823417","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/news/lenz-therapeutics-inc-nasdaqlenz-analysts-are-cutting-their","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622823417","pubTimestamp":1774607087,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its latest yearly report and things are not looking great. It was...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"QLD":"2倍做多纳斯达克100指数ETF-ProShares","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","TQQQ":"纳指三倍做多ETF","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","QYLG":"Nasdaq 100 Covered Call & Growth ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","BK4539":"次新股","QID":"两倍做空纳斯达克指数ETF-ProShares","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","PSQ":"做空纳斯达克100指数ETF-ProShares","FTEC":"Fidelity MSCI Information Techno","LENZ":"Therapeutics","BK4139":"生物科技","QDTE":"Roundhill N-100 0DTE Covered Call Strategy ETF","NVIW.SI":"NVDA 3xLongSG261006","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","IYW":"美国科技ETF-iShares",".IXIC":"NASDAQ Composite"},"translate_title":"LENZ Therapeutics, Inc.（纳斯达克股票代码：LENZ）分析师正在下调预期：以下是您需要了解的内容","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNQmain":0.6,"GPIQ":0.6,"QID":0.6,"QYLG":0.6,"QLD":0.6,"QQQY":0.6,"PSQ":0.6,"SQQQ":0.6,"JEPQ":0.6,"FTEC":0.6,"LENZ":1.5,"IYW":0.6,".IXIC":1.5,"QQQE":0.6,"QQQJ":0.6,"NQmain":0.6,"TQQQ":0.6,"QDTE":0.6,"NVIW.SI":0.6},"content_text":"LENZ Therapeutics, Inc. (NASDAQ:LENZ) just released its latest yearly report and things are not looking great.      It was a pretty negative result overall, with revenues of US$19m missing analyst predictions by 2.2%. Additionally, the business reported a statutory loss of US$2.85 per share, larger than the analysts had forecast prior to the result.     The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of.  So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGS:LENZ Earnings and Revenue Growth March 27th 2026 Taking into account the latest results, the most recent consensus for LENZ Therapeutics from six analysts is for revenues of US$30.3m in 2026. If met, it would imply a huge 59% increase on its revenue over the past 12 months.      Per-share losses are expected to explode, reaching US$3.62 per share.       Before this latest report, the consensus had been expecting revenues of US$49.5m and US$2.93 per share in losses.         There's been a definite change in sentiment in this update, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.      Check out our latest analysis for LENZ Therapeutics   The consensus price target fell 13% to US$44.43, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook.        There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business.  Currently, the most bullish analyst values LENZ Therapeutics at US$62.00 per share, while the most bearish prices it at US$20.00.   This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.      Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates.     We can infer from the latest estimates that forecasts expect a continuation of LENZ Therapeutics'historical trends, as the 59% annualised revenue growth to the end of 2026 is roughly in line with the 50% annual growth over the past three years.    By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.3% per year.  So although LENZ Therapeutics is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.     AdvertisementThe Bottom Line  The most important thing to take away is that the analysts increased their loss per share estimates for next year.        Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry.       The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of LENZ Therapeutics' future valuation.   With that said, the long-term trajectory of the company's earnings is a lot more important than next year.   At Simply Wall St, we have a full range of analyst estimates for LENZ Therapeutics going out to 2028, and you can see them free on our platform here..  We don't want to rain on the parade too much, but we did also find 1 warning sign for LENZ Therapeutics that you need to be mindful of.  New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}